At the Boao Forum for Asia Annual Conference 2024, Pascal Soriot, CEO of AstraZeneca, highlighted China’s pivotal role in driving the next wave of innovation in the biopharmaceutical industry. In an exclusive interview with CGTN, Soriot emphasized that China’s advancements in biopharmaceuticals are not only fostering innovation but also creating well-paid jobs, signaling a shift towards new quality productive forces in the country.
“China’s commitment to innovation in the biopharmaceutical sector is remarkable,” Soriot stated. “The developments we’re seeing are contributing to global health advancements and providing significant employment opportunities.”
The Boao Forum, often dubbed the “Asian Davos,” serves as a platform for leaders in government, business, and academia to discuss pressing issues in Asia and the world. This year’s conference focuses on sustainable development, innovation, and collaboration amidst global challenges.
China’s biopharmaceutical industry has been experiencing rapid growth, bolstered by government support, increased investment in research and development, and a growing talent pool. The country’s focus on innovation aligns with its broader economic strategy of transitioning from traditional manufacturing to high-tech industries.
Soriot’s comments reflect the international community’s recognition of China’s rising influence in the global pharmaceutical landscape. AstraZeneca, which has a significant presence in China, continues to invest in research collaborations and development projects within the country.
As China strengthens its position in the biopharmaceutical field, analysts anticipate increased global partnerships and a surge in innovative therapies emerging from the region. This growth presents opportunities not only for economic development but also for addressing global health challenges through collaborative efforts.
Reference(s):
cgtn.com
